News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 73–108
- Matches
- 182
- Sources here
- 17
- Companies here
- 8
Search results
Stored financial headlines
Active search
182 matching headlines
Ticker or company: RUGMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Team Ruger's Lauryl Akenhead Earns High Lady at 2026 Sheepdog Showdown
Team Ruger's Lauryl Akenhead won the High Lady title at the 2026 Sheepdog Showdown, a national PRS Pro Series point match held in the Catskill Mountains. Akenhead achieved a score of 151 using her Ruger American® Gen II rifle, highlighting the rifle's reliability and …
RGR
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.6%
Drugs Made In America Acquisition Corp (DMAA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on the dividend and stock split history for Drugs Made In America Acquisition Corp (DMAA). It notes that no dividends have been distributed over the past five years. The page also displays current stock information, including its price, market cap, …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
Drugs Made In America Acquisition Corp (DMAA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Drugs Made In America Acquisition Corp (DMAA), focusing on its P/E ratio, P/B ratio, and fair value. As of July 24th, DMAA's stock was trading at $10.709 with a market cap of $361.09 million and a TTM …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
RGR|Sturm Ruger & Company Inc|Price:38.708|Chg%:+0.478
Sturm Ruger & Company Inc (RGR) has strong fundamentals and high growth potential, though its valuation is considered fairly valued within the Leisure Products industry. The company recently turned to a loss but offers a high and stable dividend. Analysts have rated it as …
RGR
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.6%
Drugs Made In America Acquisition Corp (DMAA) Balance Sheet
This article provides the balance sheet for Drugs Made In America Acquisition Corp (DMAA), detailing its quarterly and annual financial health. It includes key financial metrics such as cash, assets, liabilities, and shareholders' equity, allowing for an analysis of the company's fundamentals and liquidity. …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
Drugs Made In America Acquisition Corp (DMAA) Cash Flow
This article provides an in-depth look at the cash flow statement for Drugs Made In America Acquisition Corp (DMAA), detailing its operating, investing, and financing activities. It presents both annual and quarterly data, highlighting significant changes such as a notable increase in operating cash …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
TradingKey
This article provides the income statement for Drugs Made In America Acquisition Corp (DMAA), including quarterly and annual financial data. It details key metrics such as operating expenses, operating profit, net non-operating interest income, income before and after tax, net income, and earnings per …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
Drugs Made In America Acquisition Corp
This article provides a company overview for Drugs Made In America Acquisition Corp (DMAA), including its stock performance and market capitalization. It notes that relevant revenue breakdown data by business segment and region have not yet been disclosed by the company. The page also …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
DMAA|Drugs Made In America Acquisition Corp|Price:10.681|Chg%:-0.009
This article provides a detailed financial overview of Drugs Made In America Acquisition Corp (DMAA), a blank check company focused on the pharmaceutical industry. It presents real-time stock quotes, key financial figures, technical indicators, and shareholder information. The company has not yet disclosed relevant …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
Sturm Ruger & Company Inc (RGR) Institutional Confidence
The article details the institutional confidence score for Sturm Ruger & Company Inc (RGR), which is 5.00, placing it 18th out of 28 in the Leisure Products industry. It notes that the institutional shareholding proportion is 67.94%, a slight decrease quarter-over-quarter. The largest institutional …
RGR
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.6%
JRM Investment Counsel LLC Purchases New Holdings in Sturm, Ruger & Company, Inc. $RGR
JRM Investment Counsel LLC has acquired a new position in Sturm, Ruger & Company, Inc. (NYSE:RGR), purchasing 397,000 shares valued at approximately $15.9 million in the first quarter of 2026. This stake now represents 4.2% of JRM’s investment portfolio and 2.49% of RGR’s outstanding …
RGR
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.6%
Sturm, Ruger & Co. (RGR.US) will release its earnings report after market close on July 29.
Sturm, Ruger & Co. (RGR.US) is scheduled to release its earnings report after the market closes on July 29. This upcoming announcement will provide investors and analysts with key financial performance indicators for the company.
RGR
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.6%
Sturm, Ruger & Company, Inc. (RGR) Expected to Announce Earnings on Wednesday
Sturm, Ruger & Company, Inc. (RGR) is expected to release its Q2 2026 earnings after the market closes on Wednesday, July 29th, with analysts forecasting earnings of $0.42 per share on $128.5 million in revenue. The company's previous quarter results were mixed, missing earnings …
RGR
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.6%
Sturm, Ruger & Company (RGR) Proxy Filing Summary
Sturm, Ruger & Company's proxy filing details voting matters for its 2026 annual meeting, including the election of directors and a proxy proposal from significant shareholder Beretta Holding regarding board composition. The company has recently refreshed its board with three new directors, now comprising …
RGR
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.6%
Lobbying Update: $60,000 of STURM RUGER & CO. INC. lobbying was just disclosed
A new Lobbying Disclosure Act filing revealed that STURM RUGER & CO. INC. disclosed $60,000 in lobbying expenditures for Q2 2026, focusing on issues such as "CFIUS Foreign investment." This article also details recent insider trading activity for RGR, showing three purchases in the …
RGR
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.6%
Sturm, Ruger to report Q2 2026 results on July 29
Sturm, Ruger & Company, Inc. is scheduled to release its second-quarter 2026 financial results on July 29, 2026, after the market closes. The company will also file its Form 10-Q and host a webcast at 4:30 p.m. ET to discuss the operating results, with …
RGR
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.6%